Table 5.
Univariate overall survival of PDAC cases (53 cases)
| N | % End of study | Mean (95% C.I) | SE | Log rank | p value | ||
|---|---|---|---|---|---|---|---|
| Gender | Male | 39 | 14.3 | 17.07 (12.654–21.482) | 2.252 | 0.248 | 0.619 |
| Female | 14 | 35.7 | 10.43 (6.345–14.512) | 2.084 | |||
|
Virology (HCV infection) |
Negative | 41 | 32.8 | 18.81 (14.056–23.568) | 2.426 | 4.201* | 0.040* |
| Positive | 12 | 0.0 | 11.29 (4.499–18.084) | 3.466 | |||
| CA19.9 | Low (< 175) | 16 | 43.8 | 20.59 (12.489–28.699) | 4.135 | 0.878 | 0.349 |
| High (≥ 175) | 11 | 0.0 | 12.23 (7.112–17.343) | 2.610 | |||
| Direct bilirubin | < 6 | 23 | 0.0 | 21.174 (15.024 − 27.324) | 3.138 | 3.975* | 0.046* |
| ≥ 6 | 27 | 14.8 | 13.019 (8.258–17.779) | 2.429 | |||
| Tumor recurrence | Absent | 20 | 20.8 | 20.20 (13.115–27.285) | 3.615 | 1.615 | 0.204 |
| Present | 18 | 14.8 | 11.61 (8.577–14.645) | 1.548 | |||
| Necrosis | Absent | 42 | 15.3 | 17.12 (12.619–21.622) | 2.297 | 0.051 | 0.821 |
| Present | 11 | 27.3 | 12.55 (7.986–17.105) | 2.326 | |||
| Epithelial Desmoplasia predominance | Desmoplasia | 28 | 0.0 | 16.39 (11.226–21.544) | 2.632 | 1.964 | 0.375 |
| Epithelial | 18 | 38.9 | 14.28 (10.158–18.398) | 2.102 | |||
| Equal | 7 | 14.3 | 10.00 (0.953–19.047) | 4.616 | |||
| TIMCs | < 10 | 20 | 24.0 | 11.51 (7.925–15.095) | 1.829 | 1.288 | 0.256 |
| ≥ 10 | 31 | 15.5 | 17.87 (12.593–23.155) | 2.694 | |||
| Tumor Size | 2–5 | 42 | 16.0 | 17.88 (13.337–22.431) | 2.320 | 3.969 | 0.046* |
| > 5 | 10 | 10.0 | 7.85 (5.556–10.144) | 1.171 | |||
| Histologic grade | I | 8 | 25.0 | 15.75 (6.156–25.344) | 4.895 | 0.076 | 0.963 |
| II | 37 | 0.0 | 16.97 (12.274 − 21.664) | 2.395 | |||
| III | 8 | 25.0 | 10.88 (7.104–14.646) | 1.924 | |||
| Low | 44 | 15.6 | 17.31 (12.880 − 21.729) | 2.257 | 0.227 | 0.634 | |
| High | 9 | 22.2 | 10.56 (7.152–13.959) | 1.736 | |||
| LVI | Absent | 34 | 18.5 | 17.997 (12.716 − 23.278) | 2.694 | 0.278 | 0.598 |
| Present | 19 | 13.2 | 12.684 (9.164–16.205) | 1.796 | |||
| Perineural invasion | Absent | 2 | 50.0 | 7.75 (0.000–17.798) | 5.127 | 0.001 | 0.981 |
| Present | 51 | 14.3 | 16.75 (12.779–20.717) | 2.025 | |||
| Resection margin | Free | 34 | 16.4 | 18.12 (13.154–23.091) | 2.535 | 0.951 | 0.329 |
| Involved | 19 | 26.3 | 10.29 (7.295–13.284) | 1.528 | |||
| N stage | N0 | 14 | 28.6 | 11.54 (6.751–16.321) | 2.441 | 0.375 | 0.829 |
| N1 | 24 | 22.2 | 16.75 (11.074–22.426) | 2.896 | |||
| N2 | 15 | 0.0 | 18.18 (10.242–26.113) | 4.049 | |||
| LN status | Negative | 14 | 28.6 | 11.54 (6.751–16.321) | 2.441 | 0.372 | 0.542 |
| Positive | 39 | 14.4 | 17.28 (12.706–21.852) | 2.333 | |||
| T stage | T1 | 1 | 100.0 | 36.0 (36.0 – 36.0) | 0.000 | 5.264 | 0.072 |
| T2 | 27 | 17.8 | 19.831(14.243–25.419) | 2.851 | |||
| T3 | 25 | 20.0 | 10.220 (6.977–13.463) | 1.654 | |||
| Stage grouping | Early | 28 | 19.3 | 20.557(15.029–26.085) | 2.820 | 4.496 | 0.034* |
| Advanced | 25 | 20.0 | 10.220 (6.977–13.463) | 1.654 | |||
|
HOXA9 (H-Score) |
Low (< 180) | 19 | 28.9 | 24.026 (16.723 − 31.330) | 3.726 | 5.948 | 0.015* |
| High (≥ 180) | 34 | 94.0 | 10.997 (8.446–13.548) | 1.302 | |||
| CD163(H-Score) | Low (< 100) | 24 | 19.9 | 20.881 (15.006 − 26.756) | 2.998 | 4.130* | 0.042* |
| High (≥ 100) | 29 | 24.1 | 9.741 (7.354–12.128) | 1.218 | |||
- CA19-9: Carbohydrate antigen 19 − 9 -HCV: Hepatitis C virus
- TIMCs: Tumor-infiltrating mononuclear cells - LVI: Lymphovascular invasion
-LN: Lymph node - T: Tumor stage